OP0223 EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (SELECT-PSA-2): A DOUBLE-BLIND, RANDOMIZED CONTROLLED PHASE 3 TRIAL - Concepedia

Concepedia

Publication | Open Access

OP0223 EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (SELECT-PSA-2): A DOUBLE-BLIND, RANDOMIZED CONTROLLED PHASE 3 TRIAL

DOI Full Paper Access

21

Citations

1

References

2020

Year

Mark C. Genovese, Apinya Lertratanakul, J. Anderson, Kim Papp, William Tillett, Filip Van den Bosch, Shigeyoshi Tsuji, Eva Dokoupilová, M. Keiserman, X. Wang,

Annals of the Rheumatic Diseases

References

	Year	Citations

Page 1